Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$818.93 USD

818.93
5,263,033

-10.81 (-1.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novartis Gets CHMP Recommendation for Kisqali in Broader Population

by Zacks Equity Research

The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.

Ahan Chakraborty headshot

NVO Stock Falls 5% in a Month: Should Investors Buy Now or Wait?

by Ahan Chakraborty

Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.

Are Medical Stocks Lagging BioLife Solutions (BLFS) This Year?

by Zacks Equity Research

Here is how BioLife Solutions, Inc. (BLFS) and Eli Lilly (LLY) have performed compared to their sector so far this year.

Viking Therapeutics Stock: Buy or Sell Before Q3 Earnings?

by Zacks Equity Research

Devoid of marketed drugs, investors will likely focus on VKTX's pipeline updates when it reports third-quarter results.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

by Zacks Equity Research

Sector ETF report for FHLC

Kinjel Shah headshot

J&J's Q3 Earnings & Sales Top: Time to Buy, Sell or Hold the Stock?

by Kinjel Shah

JNJ beats third-quarter estimates for both earnings and sales. Those who already own J&J's stock may stay invested.

Sundeep Ganoria headshot

Viking Stock Rises 29% in Three Months: Time to Buy, Hold or Sell?

by Sundeep Ganoria

VKTX continues to generate phenomenal returns, driven by encouraging updates from three promising pipeline programs.

Kinjel Shah headshot

Lilly Loses Around $14B This Week: How to Play LLY Stock

by Kinjel Shah

Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.

The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, PPH, HRTS and THNR

by Zacks Equity Research

Eli Lilly, Novo Nordisk, PPH, HRTS and THNR are part of the Zacks top Analyst Blog.

Sanghamitra Saha headshot

Inside the Booming Obesity Drug Market: Weight Loss ETFs to Win

by Sanghamitra Saha

In recent years, the pharmaceutical industry has witnessed a remarkable surge in the development of weight loss medications.

Bayer Seeks Approval for Elinzanetant for Vasomotor Symptoms in EU

by Zacks Equity Research

BAYRY submits an application seeking EMA approval of elinzanetant for treating hot flashes associated with menopause or adjuvant endocrine therapy.

FDA to Reconsider Removal of Lilly's Obesity Drug From Shortage List

by Zacks Equity Research

The FDA has agreed in court to allow compounding pharmacies to continue producing compounded versions of LLY's tirzepatide while reconsidering the drug's supply status.

J&J Beats on Q3 Earnings, Raises Sales View but Cuts EPS Guidance

by Zacks Equity Research

JNJ beats estimates for third-quarter earnings and sales. It lowers earnings expectations for 2024 but raises the sales guidance range.

Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Zacks Value Trader Highlights: Costco Wholesale, CAVA, Eli Lilly, Toll Brothers and Constellation Energy

by Zacks Equity Research

Costco Wholesale, CAVA, Eli Lilly, Toll Brothers and Constellation Energy are part of the Zacks Value Trader article.

Tracey Ryniec headshot

Stocks Beating the S&P 500 in 2024 (Excluding NVIDIA)

by Tracey Ryniec

Some say it is "easy" to beat the S&P 500 this year. Tracey picked 5 random hot stocks to test the theory.

Here's Why Eli Lilly (LLY) Fell More Than Broader Market

by Zacks Equity Research

Eli Lilly (LLY) reachead $910.69 at the closing of the latest trading day, reflecting a -0.98% change compared to its last close.

RVTY's Latest Launch to Enable APOE Genotyping of Alzheimer's Disease

by Zacks Equity Research

Revvity's latest solution for specific typing of AD-associated APOE gene is likely to allow assessment of a patient's risk for adverse effects from new anti-amyloid therapy for Alzheimer's.

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

NVS or LLY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NVS vs. LLY: Which Stock Is the Better Value Option?

Is Invesco Large Cap Growth ETF (PWB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for PWB

Pfizer Receives $1 Billion From Starboard Value, Stock Rises

by Zacks Equity Research

PFE obtains $1 billion from activist investor Starboard Value. Stock gains on hopes of a plausible turnaround of the struggling pharma giant.

Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer

by Zacks Equity Research

Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.

Should JNJ Stock Be in Your Portfolio Ahead of Q3 Earnings?

by Zacks Equity Research

JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. It remains to be seen if MedTech sales improved.